Goodwill and Intangible Assets	3 Months Ended
Goodwill and Intangible Assets	Mar. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill And Intangible Assets Disclosure [Text Block]	Note 14 – Goodwill and Other Intangible Assets Changes in the carrying amount of goodwill for the three months ended March 31, 2020 were as follows: Global Specialty Americas EMEA Asia/Pacific Businesses Total Balance as of December 31, 2020 $ 213,242 $ 140,162 $ 158,090 $ 119,718 $ 631,212 Goodwill additions 1,093 2,626 1,308 25 5,052 Currency translation adjustments (731) (3,925) (956) (3,078) (8,690) Balance as of March 31, 2021 $ 213,604 $ 138,863 $ 158,442 $ 116,665 $ 627,574 Gross carrying amounts and accumulated amortization for definite-lived intangible assets as of March 31, 2021 and December 31, 2020 were as follows: Gross Carrying Accumulated Amount Amortization 2021 2020 2021 2020 Customer lists and rights to sell $ 846,052 $ 839,551 $ 110,997 $ 99,806 Trademarks, formulations and product technology 167,144 166,448 32,533 30,483 Other 6,320 6,372 5,743 5,824 Total definite -lived intangible assets $ 1,019,516 $ 1,012,371 $ 149,273 $ 136,113 The Company amortizes definite-lived intangible assets on a straight-line basis over their useful lives. The Company recorded $ 14.8 million and $ 14.0 million of amortization expense for the three months ended March 31, 2021 and 2020, respectively. Estimated annual aggregate amortization expense for the current year and subsequent five years is as follows: For the year ended December 31, 2021 $ 59,372 For the year ended December 31, 2022 59,096 For the year ended December 31, 2023 58,927 For the year ended December 31, 2024 58,427 For the year ended December 31, 2025 57,710 For the year ended December 31, 2026 57,484 The Company has four indefinite-lived intangible assets totaling $ 205.1 million as of both March 31, 2021 and December 31, 2020, including $ 204.0 million of indefinite-lived intangible assets for trademarks and tradename associated with the Combination. Goodwill and intangible assets that have indefinite lives are not amortized and are required to be assessed at least annually for impairment. The Company completes its annual goodwill and indefinite-lived intangible asset impairment test during the fourth quarter of each year. The Company continuously evaluates if triggering events indicate a possible impairment in one or more of its reporting units or indefinite-lived or long-lived assets. The Company previously disclosed in its 2020 Form 10-K that as of March 31, 2020, the Company concluded that the impact of COVID-19 did not represent a triggering event with regards to the Company’s reporting units or indefinite-lived and long-lived assets, except for the Company’s Houghton and Fluidcare trademarks and tradename indefinite -lived intangible assets. The determination of estimated fair value of the Houghton and Fluidcare trademarks and tradename indefinite-lived assets was based on a relief from royalty valuation method, which requires management’s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to the weighted average cost of capital (“WACC”) and royalty rates, as well as revenue growth rates and terminal growth rates. In the first quarter of 2020, as a result of the impact of COVID-19 driving a decrease in projected legacy Houghton net sales during that year and the impact of the sales decline on projected future legacy Houghton net sales as well as an increase in the WACC assumption utilized in the quantitative impairment assessment, the Company concluded that the estimated fair values of the Houghton and Fluidcare trademarks and tradename intangible assets were less than their carrying values. As a result, an impairment charge of $ 38.0 million was recorded in the first quarter of 2020 to write down the carrying values of these intangible assets to their estimated fair values. As of March 31, 2021, the Company continued to evaluate the on-going impact of COVID-19 on the Company’s operations, and the volatility and uncertainty in the economic outlook as a result of COVID-19, to determine if this indicated it was more likely than not that the carrying value of any of the Company’s reporting units or indefinite-lived or long-lived intangible assets were not recoverable. The Company concluded that the impact of COVID-19 did not represent a triggering event as of March 31, 2021. While the Company concluded that the impact of COVID-19 did not represent a triggering event as of March 31, 2021, the Company will continue to evaluate the impact of COVID-19 on the Company’s current and projected results. If the current economic conditions worsen or projections of the timeline for recovery are significantly extended, then the Company may conclude in the future that the impact from COVID-19 requires the need to perform further interim quantitative impairment tests, which could result in additional impairment charges in the future.